Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Rated “Hold” by Wall Street Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned an average recommendation of “Hold” from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $20.50.

Several equities analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Finally, Leerink Partners cut their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock opened at $11.04 on Friday. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55. The company’s 50-day moving average price is $11.27 and its 200-day moving average price is $12.14.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Equities analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its Board of Directors has initiated a stock repurchase program on Wednesday, September 9th that authorizes the company to repurchase $5 million in shares. This repurchase authorization authorizes the company to repurchase up to 2.3% of its shares through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider owned 27,559 shares of the company’s stock, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,343 shares of company stock valued at $54,985 over the last quarter. 12.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KROS. BlackRock Inc. purchased a new stake in Keros Therapeutics during the 2nd quarter valued at $29,898,000. Nantahala Capital Management LLC purchased a new stake in shares of Keros Therapeutics during the second quarter worth about $15,091,483. Dimensional Fund Advisors LP grew its stake in shares of Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after purchasing an additional 263,347 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Keros Therapeutics in the second quarter worth about $2,641,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in Keros Therapeutics by 40.2% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 164,483 shares of the company’s stock worth $1,816,000 after buying an additional 47,122 shares during the period. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.